Table 2.
Mean levels (raw values) of QoL at baseline and at 24 weeks by treatment cohorts with and without PPS at baseline
| Outcome | Total
|
PPS+
|
PPS−
|
||||||
|---|---|---|---|---|---|---|---|---|---|
| Duloxetine | SSRI | Effect sizesa | Duloxetine | SSRI | Effect sizesa | Duloxetine | SSRI | Effect sizesa | |
| EQ-5D | |||||||||
| At baseline | 0.46 (0.32) | 0.47 (0.33) | −0.03 | 0.37 (0.33) | 0.40 (0.34) | −0.09 | 0.58 (0.26) | 0.54 (0.31) | 0.14 |
| At week 24 | 0.95 (0.11)b | 0.90 (0.16) | 0.35 | 0.95 (0.10)b | 0.86 (0.19) | 0.59 | 0.95 (0.12)b | 0.92 (0.12) | 0.25 |
| EQ-VAS | |||||||||
| At baseline | 43.39 (24.36) | 42.99 (26.94) | 0.02 | 40.77 (24.23) | 39.48 (27.25) | 0.05 | 47.07 (24.11) | 46.02 (26.36) | 0.04 |
| At week 24 | 75.64 (34.02)b | 69.02 (32.79) | 0.20 | 74.88 (34.94)b | 66.88 (33.28) | 0.23 | 76.75 (32.69)b | 70.62 (32.38) | 0.19 |
Notes:
a
These show effect sizes of QoL differences between treatment cohorts.
b
P<0.05 for all comparisons of outcomes between the duloxetine cohort and the SSRI cohort in the overall sample, PPS+ patients, and PPS- patients, respectively.
Abbreviations: EQ-VAS, EuroQoL-Visual Analog Scale; EQ-5D, EuroQoL-5 Dimensions; PPS, painful physical symptoms; QoL, quality of life; SSRI, selective serotonin reuptake inhibitor.